Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients

• Status: Terminated
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Suppression of stop mutations in the CFTR gene with parenteral gentamicin can be predicted in vitro and is associated with clinical benefit and significant modification of the CFTR-mediated chloride transport in nasal and sweat gland epithelium.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Gentamicins

Criteria

Inclusion Criteria:

• cystic fibrosis with CFTR codon stop mutations

Exclusion Criteria:

• Rhinitis

• nasal polyposis

• passive or active smoking

• modification of basal treatments within the previous month

• treatments with aminoglycosides within three previous months